Monitor Phase 2 MoMeNtum data in MMN (Q4'26) and CAPTIVATE Part B update (YE'26) as nearer-term catalysts; Phase 3 gMG data (2H'28) is too distant to drive near-term price action. Insider selling ahead of this announcement may signal limited upside in the near term.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $95.68entry
- T+1 · 5mo ago +1.88%α +1.10% · $97.48
- T+5 · 4mo ago −2.45%α −3.83% · $93.34
- T+20 · 4mo ago +8.56%α +8.84% · $103.87
- T+60 · 8w ago +2.79%α −1.60% · $98.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on positive Phase 2 results. Top-line data expected in 2H'28; the stock may see modest positive momentum from trial advancement but major catalysts are distant.
Key Facts
- Phase 3 EMERGE trial initiated in ~195 AChR+ gMG patients with claseprubart 300mg Q2W or Q4W
- Primary endpoint: change from baseline in MG-ADL; top-line results expected 2H'28
- Claseprubart granted Orphan Drug Designation by FDA for MG in May 2026
- Phase 2 MaGic trial showed rapid, sustained, statistically significant improvements vs placebo
- Additional catalysts: MMN Phase 2 data Q4'26, CIDP Phase 3 Part B timing update by YE'26
Financial Impact
No direct revenue impact; pipeline progression supports valuation but revenues years away
Risk Factors
- Clinical trial failure or disappointing efficacy/safety
- Competition from existing and emerging gMG therapies
- Dilution risk if additional capital is needed before data readouts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318826 |
Track record
23 reports on DNTH
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers